GlassScriptPhysician profile
Rayman W Lee
NPI 1518980291
$10,804.93
in general payments reported to CMS, 2019-2025
44 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $725 · 2021: $885 · 2022: $1,816 · 2023: $1,910 · 2024: $1,794 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,930 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,929.60 |
| Education | $142.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,625.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,357.38 | 2019-2025 | Tezspire, Andexxa, Fasenra |
| Jazz Pharmaceuticals INC. | $1,128.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $907.09 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Mylan Specialty L.P. | $709.76 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $503.97 | 2021-2025 | Dupixent |
| Harmony Biosciences LLC | $416.49 | 2023-2025 | Wakix |
| Insmed, INC. | $332.44 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $296.84 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $293.79 | 2020-2025 | Zerbaxa, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $271.40 | 2024-2025 | Aralast |
| Shionogi INC | $267.80 | 2020-2025 | Fetroja |
| Grifols USA, LLC | $264.46 | 2019-2023 | Prolastin-C Liquid |
| Electromed, INC. | $250.47 | 2019-2025 | Smartvest |
| Axsome Therapeutics, INC. | $245.59 | 2023-2025 | Sunosi |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayman Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.